Podcasts about Lundbeck

In this CME podcast, Dr. Andrew Cutler and Dr. Roger McIntyre discuss the use of potentially unsafe drug combinations in patients with treatment-resistant psychiatric conditions. They review situations where complex medication regimens may be necessary and how clinicians may proceed in these instances. By addressing these topics, the podcast offers guidance on balancing the potential benefits of combination therapies with the risks associated with polypharmacy in psychiatric care.  Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Identify common potentially unsafe drug combinations that may be considered in treatment-resistant cases Evaluate the risks and benefits of prescribing potentially unsafe drug combinations for treatment-resistant patients, considering factors such as efficacy, adverse effects, and patient-specific characteristics Develop strategies to monitor and manage patients prescribed potentially unsafe drug combinations Accreditation: In support of improving patient care, this activity has been planned and implemented by HMP Education and Neuroscience Education Institute (NEI). HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with synchronized audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour. Released: March 26, 2025*   Expiration: March 25, 2028 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD25-01 Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ HMP Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Nurse: ANCC contact hours This continuing nursing education activity awards 1.00 contact hour. Provider approved by the California Board of Registered Nursing, Provider #18006 for 1.00 contact hour. Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.00 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.00 contact hour (.10 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI and HMP Education must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and are unable to report your claimed credit after this 60-day period. Ensure your profile includes your DOB and NABP ID. Physician Associate/Assistant: AAPA Category 1 CME credits HMP Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credits for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.00 AAPA Category 1 credit. Approval is valid until March 25, 2028. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. This activity awards 1.00 CE Credit. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, HMP Education is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1.00 general continuing education credit. Non-Physician Member of the Healthcare Team: Certificate of Participation HMP Education awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, and cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI and HMP Education take responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any relevant financial relationships were mitigated prior to the activity being planned, developed, or presented. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, New York Chief Medical Officer, Neuroscience Education Institute, Malvern, Pennsylvania Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Roger S. McIntyre, MD, FRCPC Professor, Departments of Psychiatry and of Pharmacology, University of Toronto, Toronto, Ontario, Canada CEO, Braxia Scientific Corp, Toronto, ON, Canada Grant/Research: Canadian Institutes of Health Research, China National Natural Research Foundation, Global Alliance for Chronic Diseases, Milken Institute Consultant/Advisor: Alkermes, Atai Life Sciences, Axsome, Bausch Health, Biogen, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Mitsubishi Tanabe, Neumora Therapeutics, Neurocrine, NewBridge Pharmaceuticals, Novo Nordisk, Otsuka, Pfizer, Purdue, Sage, Sanofi, Sunovion, Takeda, Viatris The remaining Planning Committee members, Content Editors, Peer Reviewer, NEI and HMP planners/staff have no financial relationships to disclose. NEI and HMP Education planners and staff include Gabriela Alarcón, PhD, Ali Holladay, Andrea Zimmerman, EdD, CHCP, Brielle Calleo, and Steven S. Simring, MD, MPH. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported solely by the provider, NEI.

Hvad tænker toppen af dansk erhvervsliv om truslerne fra præsident Donald Trump? Nu sætter en af landets tunge topchefer ord på den udenrigspolitiske krise, og siger, at ”den tager al den opmærksomhed, vi har, og lidt til.” Lars Rasmussen er bestyrelsesformand for de to C25-virksomheder Coloplast og Lundbeck. Og for WSAudiology, der producerer høreapparater. De tre virksomheder har store økonomiske interesser i USA, og Lars Rasmussen har hånden på kogepladen. 02.22: Om geopolitik: Du skal kunne tage imod mange stød og tåle dem. 15.00: Om Donald Trump: Ja, det er vildt. Han udtaler sig i øst og vest. Uforudsigeligheden er den største udfordring. 18.00: Om ledelse i krisen: Hvis du regner på alle tænkelige scenarier, har du ikke tid til at lede forretningen. Derfor: Is i maven. 32.00: Niels' opsamling. Producer: Arjuna Alexander Kolkur Sørensen. Få Niels Lundes nyhedsbrev. Tilmelding på borsen.dk/nyhedsbreve.  

The EMJ GOLD podcast is back for a new season! In the first episode of Season 9, the team are welcomed by Charl van Zyl, President and CEO, Lundbeck Pharmaceuticals, to discuss advances in the treatment of neurological disorders, making this the 'decade of the brain', and how industry can do more to support patients living brain conditions.  Together, Charl and Isabel explore his career journey in the pharmaceutical industry, Lundbeck's plans for the future, the role of digital health technology and much more.  A little more on EMJ GOLD's guest...  Charl van Zyl joined Lundbeck as President and CEO in September 2023. He brings more than 23 years of experience from commercial international management roles within the pharmaceutical industry, most recently in the field of immunology and neurology from UCB where he served as Executive Vice President and Head of Neurology globally, responsible for corporate activities in Europe and international markets.  Charl is British and holds a degree in Medical Biochemistry from the University of Cape Town, South Africa. He has lived and worked in South Africa, United States, Japan, Switzerland, Belgium and now Denmark. 

Evaluation and Credit:  https://www.surveymonkey.com/r/Medchat73 Target Audience   This activity is targeted toward primary care physicians and advanced providers.  Statement of Need The relationship between female hormones and migraines is complex and primary care providers may not be aware of the latest research regarding the role of hormonal changes during different life stages (e.g., menarche, pregnancy, and menopause) and their impact on migraine patterns or the latest management guidelines. By addressing these needs, the podcast will equip clinicians with the tools to better diagnose, treat, and prevent hormonal migraines, ultimately improving patient care and outcomes. Objectives At the conclusion of this offering, the participant will be able to:  Review the diagnostic criteria of migraines and characteristics of hormonal migraines. Discuss treatment and prevention strategies for hormonal migraines, including during pregnancy. Describe the role hormones in the treatment of migraines.   ModeratorBrian Plato, D.O., FAHS Neurologist Medical Director Headache Medicine, Neurology Norton Neuroscience Institute Norton Healthcare Louisville, Kentucky  SpeakersKris Barnsfather, M.D. Obstetrician Gynecologist Women's Care Physicians of Louisville Norton Healthcare Louisville, Kentucky Christopher Rhyne, M.D. Neurologist Headache Medicine, Neurology Norton Neuroscience Institute Norton Healthcare Louisville, Kentucky Moderator and Planner Disclosures  The planners and moderator of this activity do not have any relevant financial relationships with ineligible companies to disclose.   Speaker DisclosureThe speaker Kris Barnsfather, M.D. does not have any relevant financial relationships with ineligible companies to disclose.  The speaker Christopher Rhynes, M.D., has relevant financial relationships with ineligible companies Lundbeck and Abbvie as a speaker/consultant. Relevant financial relationships with ineligible companies Pfizer and Lilly as a speaker/consultant; and Amgen, Teva and Impel as a speaker have ended. All relevant financial relationships have been mitigated. Commercial Support  There was no commercial support for this activity.  Physician Credits Accreditation Norton Healthcare is accredited by the Kentucky Medical Association to provide continuing medical education for physicians. Designation Norton Healthcare designates this enduring material for a maximum of .75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For more information about continuing medical education, please send an email to cme@nortonhealthcare.org.  Nursing CreditsNorton Healthcare Institute for Education and Development is approved with distinction as a provider of nursing continuing professional development by the South Carolina Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation. This continuing professional development activity has been approved for .75 contact hours. In order for nursing participants to obtain credits, they must claim attendance by attesting to the number of hours in attendance.   For more information related to nursing credits, contact Sally Sturgeon, DNP, RN, SANE-A, AFN-BC at (502) 446-5889 or sally.sturgeon@nortonhealthcare.org. Resources for Additional Study/References Migraine: navigating the hormonal minefield https://pubmed.ncbi.nlm.nih.gov/31753858/ Role of Estrogens in Menstrual Migraine https://pubmed.ncbi.nlm.nih.gov/35456034/ Date of Original Release | Dec. 2024; Information is current as of the time of recording. Course Termination Date | Dec. 2027 Contact Information | Center for Continuing Medical Education; (502) 446-5955 or cme@nortonhealthcare.org Norton Healthcare, a not for profit health care system, is a leader in serving adult and pediatric patients throughout Greater Louisville, Southern Indiana, the commonwealth of Kentucky and beyond. More information about Norton Healthcare is available at NortonHealthcare.com.

In this CME podcast, Dr. Andrew Cutler interviews Dr. Jonathan Meyer about the history of muscarinic receptor science in schizophrenia and how that informs the mechanisms of action of novel muscarinic-targeting drugs for this disorder. They also discuss the efficacy and safety of these drugs and provide practical strategies for prescribing xanomeline-trospium.  Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Discuss the history of muscarinic receptor science and the role of muscarinic receptors in schizophrenia treatment Differentiate novel and in-development muscarinic-targeting treatments for schizophrenia based on their unique mechanisms of action, efficacy, and tolerability data   Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour Released: November 27, 2024*   Expiration: November 26, 2027 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-SCHIZ01  Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.0 ANCC contact hour Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.0 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.0 contact hour (.10 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.0 AAPA Category 1 credit. Approval is valid until November 26, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1 general continuing education credits. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD specializing in psychiatry and psychopharmacology — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Jonathan M. Meyer, MD Voluntary Clinical Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA Consultant/Advisor: AbbVie, Alkermes, Bristol Myers Squibb, Intra-Cellular, Neurocrine, Sumitomo, Teva Speakers Bureau: AbbVie, Alkermes, Axsome, Bristol Myers Squibb, Intra-Cellular, Neurocrine, Teva The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O'Brien, Gabriela Alarcón, PhD, Meghan M. Grady, BA, Andrea Zimmerman, EdD, CHCP, and Brielle Calleo. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported by an educational grant from Bristol Myers Squibb.

Hvilken vej peger den vigtige amerikanske inflation?Slut med aktieeurofori eller blot en nødvendig pause? De faldende markeder tirsdag viste investorerne, at trænerne ikke bare vokser ind i himlen, men er det for alvor slut med opturen eller var det blot let tråd på bremsen op mod dagens amerikanske inflationstal? Millionærklubben ser på sagen og tjekker dagens aktuelle regnskaber fra Lundbeck med aktiechef Michael Friis Jørgensen fra HC Andersen Capital i studiet, og fra Svitzer med selskabets CEO, Kasper Friis Nilaus på telefonen.  Vært: Bodil Johanne GantzelSee omnystudio.com/listener for privacy information.

In this CME episode, Drs. Andrew Cutler and Roger McIntyre discuss the challenges and importance of diagnosing bipolar disorder as early as possible in the course of the illness. They also review strategies to achieve a correct diagnosis to provide the most efficacious and tolerable treatments available for bipolar disorder. Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Employ effective screening tools and assessment strategies to enhance diagnostic accuracy and achieve early diagnosis of bipolar disorder Develop patient-centered treatment plans that incorporate current evidence and individual patient factors Utilize shared decision-making approaches to optimize treatment outcomes for patients with bipolar disorder Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour Released: November 01, 2024*   Expiration: October 31, 2027 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-BD Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.0 ANCC contact hour Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.0 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.0 contact hour (.10 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.0 AAPA Category 1 credit. Approval is valid until OCtober 31, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1 general continuing education credits. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, New York Chief Medical Officer, Neuroscience Education Institute, Malvern, Pennsylvania Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Roger S. McIntyre, MD, FRCPC Professor, Departments of Psychiatry and of Pharmacology, University of Toronto, Toronto, Ontario, Canada CEO, Braxia Scientific Corp, Toronto, Ontario, Canada Grant/Research: Canadian Institutes of Health Research, China National Natural Research Foundation, Global Alliance for Chronic Diseases, Milken Institute Consultant/Advisor: Alkermes, Atai Life Sciences, Axsome, Bausch Health, Biogen, Eisai, Intra-Cellular, Janssen, Kris, Lundbeck, Mitsubishi Tanabe, Neumora Therapeutics, Neurocrine, NewBridge Pharmaceuticals, Novo Nordisk, Otsuka, Pfizer, Purdue, Sage, Sanofi, Sunovion, Takeda, Viatris The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O'Brien, Gabriela Alarcón, PhD, Andrea Zimmerman, EdD, CHCP, and Brielle Calleo. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported by an unrestricted educational grant from Alkermes, Inc.

In partnership with the PA Conference for Women, we bring you “Women Who Inspire.” I speak with Debra Barrett, VP of Corporate Affairs at Otsuka, about their collaboration with Lundbeck to feature renowned entrepreneur, author, and Shark Tank star Barbara Corcoran as a keynote speaker at the PA Conference for Women. In recognition of Alzheimer's Awareness Month, Barbara will discuss her own experiences as an Alzheimer's caregiver. Barrett also shares valuable resources available for caregivers.  Otsuka's Social Media and Website:Caregiver Resources: https://otsuka-us.com/valued-minds/caregiverWebsite: https://otsuka-us.comX: @OtsukaUSInstagram: @otsuka_usFacebook: OtsukaUSLinkedIn: Otsuka Pharmaceutical Companies (U.S.)PA Conference for Women Social Media:Website: PAConferenceforWomen.orgFacebook: Pennsylvania Conference for WomenInstagram: @pennwomenX: @PennWomen

Did you know that a disproportionate number of people of color are on the transplant waitlist, particularly for kidneys? This episode dives into the critical need for organ donation and the impact of faith-based communities in spreading awareness through the Gift of Life Donor Sabbath. I speak with Naja Killebrew, Multicultural Affairs Specialist at the Gift of Life Donor Program, and Rev. Cheryl Hurley, Director of Sponsorship at Teaching to Change Lives, INC. Rev. Hurley shares her passion for empowering individuals through education and spiritual guidance. We also highlight the upcoming Donor Sabbath Gospel Concert, happening on Saturday, November 16th, from 4-6 PM at the African Episcopal Church of St. Thomas on Lancaster Avenue.Find more information on Donor Sabbath at www.Donors1.org.  In partnership with the PA Conference for Women, we bring you “Women Who   Inspire.” I speak with Debra Barrett, VP of Corporate Affairs at Otsuka, about their collaboration with Lundbeck to bring renowned entrepreneur and Shark Tank star Barbara Corcoran to the PA Conference for Women as a keynote speaker. November is Alzheimer's Awareness Month, and Barbara will share her own experience as an Alzheimer's caregiver. Barrett also discusses valuable resources available for caregivers.   Otsuka's Social Media and Website:Caregiver Resources: https://otsuka-us.com/valued-minds/caregiverWebsite: https://otsuka-us.comX: @OtsukaUSInstagram: @otsuka_usFacebook: OtsukaUSLinkedIn: Otsuka Pharmaceutical Companies (U.S.)  PA Conference for Women Social Media:Website: PAConferenceforWomen.orgFacebook: Pennsylvania Conference for WomenInstagram: @pennwomenX: @PennWomen  First, we hear from Commissioner Omar Sabir, who shares essential advice for voters ahead of the November 5th Election. For more information, visit https://vote.phila.gov.

The 17th Annual Philadelphia Asian American Film Festival returns to the city from November 7th to 17th! This year's theme, Reflection, invites audiences to explore transformative moments that shape our identities and aspirations. Through a lineup of inspiring, conversation-sparking films, the festival celebrates the rich diversity of the Asian American, Native Hawaiian, and Pacific Islander experience. Join this cinematic journey that promises to leave a lasting impact. I speak with Nani Shin, Executive Director of the Philadelphia Asian American Film Festival, who shares insights into this year's program.Get your tickets today at paaff.org.   In partnership with the PA Conference for Women, we bring you “Women Who Inspire.” I speak with Debra Barrett, VP of Corporate Affairs at Otsuka, about their collaboration with Lundbeck to feature renowned entrepreneur, author, and Shark Tank star Barbara Corcoran as a keynote speaker at the PA Conference for Women. In recognition of Alzheimer's Awareness Month, Barbara will discuss her own experiences as an Alzheimer's caregiver. Barrett also shares valuable resources available for caregivers. Otsuka's Social Media and Website:Caregiver Resources: https://otsuka-us.com/valued-minds/caregiverWebsite: https://otsuka-us.comX: @OtsukaUSInstagram: @otsuka_usFacebook: OtsukaUSLinkedIn: Otsuka Pharmaceutical Companies (U.S.)PA Conference for Women Social Media:Website: PAConferenceforWomen.orgFacebook: Pennsylvania Conference for WomenInstagram: @pennwomenX: @PennWomen  First, we hear from Commissioner Omar Sabir, who provides essential last-minute advice for voters ahead of the November 5th Election. For more information, visit vote.phila.gov.

On this week's episode of Biotech Hangout, hosts Daphne Zohar, Josh Schimmer, Brad Loncar, John Maraganore, Paul Matteis, Mike Yee and Tess Cameron open up with market commentary and how derivatives, debates and dynamics are impacting stocks including Scholar Rock, Biohaven, Roche and Regeneron. The group also highlights CeriBell, which is the first medtech IPO in years. The hosts turn to neuro sentiment with a look at Lundbeck's acquisition of Longboard at an approximate value of $2.5 billion net of cash. The conversation turns to the idea of competitors benefiting from M&A and data, with this week's example of Bright Minds Bioscience's market cap going from $4 million to $172 million. The group also discusses the FDA's approval of Novocure's Optune device for the treatment of metastatic non-small cell lung cancer before turning to a conversation on vaccines, including Moderna's upcoming Phase 3 CMV data. Wave Life Sciences first-ever therapeutic RNA was also covered, which led to a discussion on how important milestones open new doors. Other topics discussed include the launch of City Therapeutics, Benitec's gene therapy update, and more. *This episode aired on October 18, 2024.

In this CME episode, Dr. Andy Cutler interviews Dr. Leslie Citrome about the impact of tardive dyskinesia on patient-reported outcomes and quality of life. They discuss how to correctly assess and diagnose tardive dyskinesia, as well as effective management strategies that incorporate the individual needs of patients.  Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Understand the physical, psychological, social, and occupational impacts of tardive dyskinesia (TD) on patients Identify clinical tools and patient-reported outcome measures to assess the severity and impact of TD Formulate evidence-based treatment strategies for TD that enhance patient outcomes and quality of life Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.   Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 1 hour Released: October 23, 2024*   Expiration: October 22, 2027 *NEI maintains a record of participation for six (6) years.   CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-TD   Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.0 ANCC contact hour Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.0 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.0 contact hour (.10 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.0 AAPA Category 1 credit. Approval is valid until OCtober 22, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1 general continuing education credits. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Leslie Citrome, MD, MPH Clinical Professor, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY Consultant/Advisor: AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Delpor, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, INmune Bio, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Luye, Lyndra, MapLight, Marvin, Medavante-ProPhase, Merck, Mitsubishi-Tanabe Pharma, Neumora, Neurocrine, Neurelis, Noema, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sumitomo/Sunovion, Supernus, Teva, University of Arizona, Vanda Speakers Bureau: AbbVie/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, Teva Stockholder: Bristol-Myers Squibb, Eli Lilly, J & J, Merck, Pfizer, Reviva (options) The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O'Brien, Gabriela Alarcón, PhD, Andrea Zimmerman, EdD, CHCP, and Brielle Calleo. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported by an unrestricted educational grant from Teva Pharmaceuticals.

...en nobelpris-modtager, Lundbecks rejse fra kiks til milliardopkøb, Danish Crowns krise og hænderne over hovedet på topdirektører, hvis Trump vinder. Med få uger til valgdagen i USA, har senator Elizabeth Warren nu kastet sig over Novos fabriksopkøb til 114 milliarder kroner. Og hun er ikke tilfreds. Topdirektør Lars Fruergaard har lige haft Bernie Sanders på nakken - og nu er det så Warren. Stéphanie Surruge kommer forbi og tegner et portræt af senatoren. Medicinalgiganten Lundbeck har købt en virksomhed til 17 milliarder danske kroner. Vi vender købet og tager en tur tilbage til dengang, Lundbeck solgte kiks og støvsugere. Vi skal også forbi Danish Crowns krise. Vi ser på to grafer, der ikke ser for godt ud. Men så ringer vi til en ekspert, der ser lidt lysere på fremtiden for slagterigiganten. Til slut tager vi til USA igen - for hvad vil det betyde for detailsektoren, hvis henholdsvis Harris og Trump kommer til magten? Hvem skal Lego, Bestseller og Pandora heppe på? Og så er der en hilsen fra en Nobelpris-modtager... Vært: Ulrik Rosenkvist Schultz. Fast gæst: Sune Aagaard. Medvirkende: Stéphanie Surruge, international korrespondent og vært på podcasten Stjerner og Striber, Henning Otte Hansen, seniorrådgiver ved Københavns Universitet og Tine Choi Danielsen, chefstrateg hos PFA.

There is a growing mandate among researchers and VCs to provide proof of causal human biology for new targets. On the latest BioCentury This Week podcast, BioCentury's editors discuss the different strategies being deployed to identify causal links to disease using observational patient data or human cell models, including the challenges that come with each approach and the various computational methodologies companies are using.They also discuss the outcome of FDA's advisory committee meeting on Barth syndrome candidate elamipretide from Stealth Biotherapeutics, and the implications of the discussion for review of ultrarare disease therapies more broadly.Diving into the deal of the day, the editors review the proposal by H. Lundbeck to acquire Longboard Pharmaceuticals for $2.6 billion, and discuss how the biotech's therapy for developmental epilepsies may stack up against competitors.View full story: https://www.biocentury.com/article/65384300:00 - Introduction00:34 - Causal Biology and Big Data17:52 - FDA's Ultra-Rare Decision27:29 - Lundbeck Acquires LongboardTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Ohne Aktien-Zugang ist's schwer? Starte jetzt bei unserem Partner Scalable Capital. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Aktien + Whatsapp = Hier anmelden. Lieber als Newsletter? Geht auch. Das Buch zum Podcast? Jetzt lesen.  EZB, Kamala und China sorgen für gute Stimmung beim Bitcoin. DAX macht auch Rekorde. Voestalpine und britische Wettanbieter machen alles andere als Rekorde. Dafür gibt's Deals bei Lundbeck & SoFi und teure KI bei Adobe. Wells Fargo (WKN: 857949) war mal die wertvollste Bank der USA. Dann kamen Skandale und ein Vermögenslimit. Kommt jetzt der Turnaround ohne Limit? 40 Millionen für eine Salat-Bar? Cava (WKN: A3EGWY) macht's möglich. Und trotz der horrenden Bewertung ist vielleicht sogar bisschen Upside möglich. Diesen Podcast vom 15.10.2024, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Danish pharmaceutical company Lundbeck has announced a $2.6 billion deal to acquire Longboard Pharmaceuticals, gaining access to their epilepsy drug currently in late-stage development. The FDA's accelerated approval pathway has seen withdrawals and failures recently, despite having helped bring nearly 300 new drugs to market since 1992.In other news, Novo Nordisk has acquired Catalent's oral solids manufacturing facility in New Jersey, while Lilly's tirzepatide could face shortages leading to opportunities for compounders. Additionally, Pfizer has won FDA approval for a hemophilia therapy amid activist investor challenges, and Evonik is set to lay off up to 260 employees in Germany. Bluebird's gene therapy has been linked to blood cancers in children.The Institute for Cancer Research is researching preventive and regenerative medicine to extend healthy lifespan.

**NOTICIAS ECONÓMICAS Y FINANCIERAS** ☕️ SpaceX logró un hito histórico en su quinto vuelo de prueba al lanzar el gigantesco cohete Starship y recuperar el propulsor de primera etapa Super Heavy usando brazos mecánicos llamados "chopsticks". Este avance acerca a la empresa de Elon Musk a su objetivo de desarrollar cohetes reutilizables que podrían reducir los costos de transporte espacial. Además, fortalece los planes de la NASA para reanudar sus misiones lunares y explorar Marte. Aunque los primeros tres vuelos de prueba terminaron en explosiones, el cuarto en junio de 2024 y el más reciente han sido exitosos, allanando el camino para futuras pruebas de aterrizajes controlados. NASA ya ha seleccionado a Starship para su misión tripulada a la Luna, Artemis 3, programada para septiembre de 2026. Berkshire Hathaway ($BRK.A, $BRK.B), la empresa de Warren Buffett, realizó una compra significativa de acciones de la compañía de radio y radiodifusión SiriusXM ($SIRI) esta semana, adquiriendo un total de $86.73 millones en acciones, lo que elevó su participación total a 192 millones de acciones. La empresa compró 870,000 acciones el miércoles, 1,435,000 acciones el jueves y 1,259,000 acciones el viernes. Berkshire había revelado su participación en $SIRI en noviembre de 2023, luego de que la empresa se convirtiera en pública e independiente tras su transacción con Liberty Media en septiembre. La gigante de software empresarial, ServiceNow ($NOW), anunció una inversión de $1.5 billones en el Reino Unido durante los próximos cinco años, como muestra de confianza hacia el primer ministro Keir Starmer, quien busca atraer inversión extranjera. El dinero se destinará a expandir su negocio en el Reino Unido, incluyendo nuevas oficinas y un crecimiento en la plantilla actual de 1,000 empleados. Además, la inversión se enfocará en la localización de procesamiento de datos para sus modelos de lenguaje grande (LLMs) y la incorporación de GPUs de Nvidia en centros de datos en Londres y Newport. Este esfuerzo busca desarrollar LLMs específicos para clientes y gobiernos del Reino Unido, promoviendo la "soberanía" de la IA en Europa. Lundbeck ($HLBBF) adquirirá Longboard Pharmaceuticals ($LBPH) por un valor de $2.6 billones. Las acciones de $LBPH subieron un 47.81% en el premercado tras el anuncio. Lundbeck lanzará una oferta pública para adquirir todas las acciones en circulación de Longboard. El acuerdo, aprobado por unanimidad por ambas juntas directivas, se cerrará en el cuarto trimestre de este año. A través de esta adquisición, Lundbeck accederá a bexicaserina, un tratamiento en desarrollo para las convulsiones asociadas con epilepsias raras como el síndrome de Dravet y Lennox-Gastaut. La empresa financiará el acuerdo con recursos de caja y su línea de financiamiento bancario, y estima costos de integración de $80 millones que impactarán principalmente en 2024.El ministro de Finanzas de China, Lan Fo'an, ofreció un discurso esperado sobre el plan del país para apoyar la economía, pero no dio detalles sobre cuánto gastará el gobierno para revertir las tendencias deflacionarias. Afirmó que el gobierno tiene una gran capacidad para aumentar el gasto y aliviar las deudas de los gobiernos locales, estabilizar el valor inmobiliario y recapitalizar los principales bancos. Aunque prometió medidas audaces, algunos economistas expresaron decepción por la falta de anuncios sobre el impulso al consumo personal, que consideran clave para el crecimiento a largo plazo. Más detalles se esperan cuando el parlamento chino se reúna este mes. Las acciones que tenemos hoy con predicción bullish en Pre-Market Runners:**

Que tal enviar uma mensagem ;-)Conversei com o Presidente da Lundbeck no Brasil, uma empresa de 100 anos e 22 anos no Brasil especializada em doenças mentais.Josiel Florenzano fala sobre sua carreira, mas também sobre a cultura dinarmaquesa e o sucesso institucional da Lundbeck na categoria de sistema nervoso central.Obrigado por ouvir, acesse @viaoral ou nosso site viaoral.com.br

In this CME episode, Dr. Andrew Cutler interviews Dr. Charles Vega about the challenges of identifying bipolar disorder in primary care and how to over come them. They also discuss strategies for initiating and managing pharmacological treatment long term in collaboration with patients and psychiatric specialists. Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objective: After completing this educational activity, you should be better able to: Identify the key symptoms and diagnostic criteria for bipolar disorder to accurately screen and diagnose patients presenting in primary care settings Describe strategies for initiating and managing pharmacological treatment of bipolar disorder, including appropriate use of mood stabilizers, antipsychotics, and monitoring for side effects and adherence Explain the role of the primary care provider in coordinating care for bipolar disorder patients, including providing psychoeducation, determining appropriate level of care, and collaborating with mental health specialists when needed Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit.   Estimated Time to Complete: 45 minutes Released: September 04, 2024*   Expiration: September 03, 2027 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-PrimCare Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 0.75 ANCC contact hour Nurse Practitioner: ACCME AMA PRA Category 1 Credits™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 0.75 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 0.75 contact hour (.075 CEU). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 0.75 AAPA Category 1 credit. Approval is valid until September 03, 2027. PAs should only claim credit commensurate with the extent of their participation. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any relevant financial relationships were mitigated prior to the activity being planned, developed, or presented. Disclosures are from the original live presentation, unless otherwise noted. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NYChief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Charles P. Vega, MD Clinical Professor, School of Medicine, University of California - Irvine, Orange, CA Consultant/Advisor: Boehringer Ingelheim, Exact Sciences The remaining Planning Committee member(s), Content Editor(s), Peer Reviewer(s), and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Gabriela Alarcón, PhD, Andrea Zimmerman, EdD, Samantha Joy, and Brielle Calleo. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported solely by the provider, NEI.

Starbucks har hyret en ny CEO og givet ham 700.000.000 kroner i velkomstgave. Fremtiden for 7-11 er lidt uvis, da Japan har åbnet op for muligheden for at sælge sine selskaber til udlændinge. De tidligere kæmpevindere, SAAB og Rheinmetall, går usikkerhed og en hård fremtid i møde. Over tre chokoladecroissanter er stemningen enormt høj i programmet, der også vender Lundbeck, Carlsberg, Pandora, Harboe og andre nationalklenodier.

In this CME episode, Dr. Andrew Cutler interviews Dr. Laxman Bahroo about the current landscape of tardive dyskinesia, including screening, diagnosis, and treatment. Practical strategies based on the latest data are reviewed at length, particularly for long-term management of tardive dyskinesia.  Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Consider the individual patient profile and symptoms when determining a treatment plan for patients with tardive dyskinesia Integrate latest safety, efficacy, and tolerability data of VMAT2 inhibitors into decision-making processes when considering treatment options for tardive dyskinesia Evaluate practical strategies for patient follow-up and long-term VMAT2 inhibitor treatment Evaluate and integrate recent updates and advancements regarding evidence-based treatment strategies for tardive dyskinesia Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit. Estimated Time to Complete: 1 hour Released: June 26, 2024*   Expiration: June 25, 2027 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-02-TD Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.0 ANCC contact hours Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 1.0 continuing education hour of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.0 contact hour (.10 CEUs). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.0 AAPA Category 1 credit. Approval is valid until June 25, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1.0 general continuing education credits. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity. Interprofessional Continuing Education: IPCE credit for learning and change This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change. Peer Review: The content was peer-reviewed by an MD, MPH specializing in forensics, psychosis, schizophrenia, mood disorders, anxiety, cognitive disorders — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Laxman B. Bahroo, DO, MS, FAAN Professor and Residency Program Director, Department of Neurology, MedStar Georgetown University Hospital, Washington, DC Consultant/Advisor: AbbVie, Amneal, Ipsen, Kyowa Kirin, Merz, Neurocrine, Revance, Supernus Speakers Bureau: AbbVie, Acadia, Acorda, Amneal, Ipsen, Kyowa Kirin, Merz, Neurocrine, Supernus, Teva The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O'Brien, Meghan Grady, Brielle Calleo, and Andrea Zimmerman, EdD. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences.

In this CME episode, Dr. Andrew Cutler interviews Desiree Matthews, PMHNP-BC on the importance of engaging patients across all facets of tardive dyskinesia management beginning with screening to symptoms monitoring to treatment. The role of patient experience and preferences in shared decision-making regarding treatment for tardive dyskinesia is discussed at length.  Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Recognize the significance of comprehensive measures that assess both healthcare practitioner-perceived severity of tardive dyskinesia symptoms and the patient-reported impact of tardive dyskinesia on daily life Engage in informed discussions with patients about the rationale behind incorporating additional medications to manage side effects arising from primary antipsychotic medication Consider all facets of patient health, including physical, mental, and social well-being, when formulating strategies for managing tardive dyskinesia symptoms Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit. Estimated Time to Complete: 1 hour. Released: June 05, 2024*   Expiration: June 04, 2027 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-01-TD Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.00 ANCC contact hours Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 0.5 continuing education hour(s) of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.00 contact hour(s) (.10 CEUs). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.00 AAPA Category 1 credit(s). Approval is valid until June 04, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1 general continuing education credits. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity. Peer Review: The content was peer-reviewed by an MD specializing in psychiatry — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any relevant financial relationships were mitigated prior to the activity being planned, developed, or presented. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Desiree M. Matthews, MSN, PMHNP-BC Founder and Clinical Director, Different MHP, PC, Charlotte, NC Consultant/Advisor: Alkermes, Biogen, Boehringer Ingelheim, Karuna, Indivior, Janssen Pharmaceuticals, Neurocrine Biosciences, Sage Therapeutics, Takeda, Teva Speakers Bureau: AbbVie, Axsome, Neurocrine Biosciences, Teva The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O'Brien, Meghan Grady, and Andrea Zimmerman. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences.

In this episode of the Psychedelic Medicine Podcast, Dr. Hans Eriksson joins to discuss the potential of non-dissociative ketamine. Dr. Eriksson, Chief Medical Officer at HMNC Brain Health, is a highly respected drug developer and clinical psychiatrist with over 20 years of pharmaceutical experience. Prior to HMNC Brain Health, Dr. Eriksson served as Chief Medical Officer at COMPASS Pathways and previously as Senior Director of Clinical Research at Lundbeck and Medical Science Director at AstraZeneca. In this conversation, Dr. Eriksson shares what inspired him to move from clinical practice to drug development, and why he sees so much potential in developing non-dissociative forms of ketamine. He discusses the ways the dissociative effects of ketamine decrease the accessibility of this treatment due to the fact that these changes in perception are undesirable for a significant portion of patients. Dr. Eriksson also shares results from preliminary studies of non-dissociative ketamine which showed efficacy in inducing anti-depressant effects. In closing, Dr. Eriksson discusses why he thinks the experiential element of the classical psychedelics play an important role in their efficacy as mental health treatments, but why this might not be the case when it comes to ketamine.    In this episode you'll hear: The history of ketamine The pharmacology of ketamine's dissociative effect The relationship between ketamine dose and antidepressant effect  The possibility of bladder issues and addiction with ketamine and whether non-dissociative forms of ketamine would also have these potentials How Dr. Eriksson thinks about combining psychotherapy with ketamine treatments   Quotes: “We are aiming for a similar exposure to the drug as you achieve with, for instance, an intravenous administration, but we are achieving a much lower peak concentration, maximum concentration of the compound. So that is one of the characteristics of our formulation.” [10:58] “Our view is that it's probably better to try to use the metabolism in the body as a tool to achieve very low exposure to ketamine but high exposure to the downstream metabolites.” [23:19]   Links: Dr. Eriksson on LinkedIn HMNC Brain Health on LinkedIn HMNC Brain Health website Previous episode: Potential Benefits of Non-Hallucinogenic Psychedelics with Kurt Rasmussen, PhD Psychedelic Medicine Association Porangui

Friske regnskabstal ude fra FLSmidth og Lundbeck. Millionærklubben hopper i tallene og tjekker resultaterne fra de to selskaber med hhv. Roland M Andersen, CFO i FLSmidth, og Søren Løntoft, aktieanalytiker i Sydbank. I studiet afslører aktiechef i HC Andersen Capital, Michael Friis Jørgensen, hvilke positioner han for nylig har taget ind i konkurrencen, og så bliver der ellers varmet op til ugens måske vigtigste nøgletal, forbrugerpriser fra USA, der offentliggøres onsdag eftermiddag. Vært: Bodil Johanne Gantzel. See omnystudio.com/listener for privacy information.

Join us for part 2 of BrainStorm's interview with Dr. Brent Forester, Chairman of the Department of Psychiatry, and Director of Behavioral Health at Tufts Medical Center. Host Meryl Comer and Dr. Forester discuss the need for a change of mindset by the medical community and the public in general when it comes to dementia.Dr. Forester, author of The Complete Family Guide to Dementia, Everything You Need to Know to Help Your Parent and Yourself, explains how countless families grappling with the complexities of caring for a parent with dementia are frustrated by the scarcity of neurologists. He emphasizes the importance of focusing on what can be done for people with dementia rather than dwelling on limitations. His advice to caregivers - adopt a "caring smarter, not harder" approach. Comer and Dr. Forester delve into strategies for observing and addressing behavioral symptoms in dementia patients, as well as as new FDA approved treatment for psychosis and agitation in AD. Whether you're directly impacted by dementia or not, you'll leave this episode with valuable insights. Tune in today!This episode is sponsored by Otsuka and Lundbeck. Support the show

If you're facing the challenge of caring for a parent with dementia, you are not alone. In this episode of BrainStorm Brent Forester, MD, MSc, Psychiatrist in Chief, Chairman of the Department of Psychiatry, and Director of Behavioral Health at Tufts Medical Center, discussed the complexity of dementia care and the importance of a holistic approach with host Meryl Comer. Dr. Forester, author of The Complete Family Guide to Dementia, everything You Need to Know to Help Your Parent and Yourself, provided crucial insight for effective management of behaviors, and tips to facilitate communication with healthcare providers. The needs of both patients and caregivers must always be considered during the decision-making process.  You won't want to miss this episode!This episode is sponsored by Otsuka and Lundbeck.Produced by Susan Quirk and Amber RonigerSupport the show

Vi sætter lyd til to af ugens bedste historier på Finans Impact.Lyt med, når klimaredaktør Jakob Martini fortæller om, at en række danske virksomheder er smidt ud af det gode klimaselskab. Hvad sker der for det?Journalist Sille Wulff Mortensen fortæller om, at virksomhederne står med en ny udfordring i at rumme et stigende antal medarbejdere med diagnoser.(01:30) Kraftig stigning i antallet af medarbejdere med ADHDOpmærksomhedsforstyrrelser er en del af livet for mange voksne mennesker. Det skaber nye krav til virksomheder om at rumme medarbejdere med diagnoser. Lundbeck er en af de virksomheder, som arbejder målrettet med at inkludere medarbejdere med neurologiske lidelser. Det kan være en stor fordel, lyder det fra Lundbecks topchef Charl van Zyl, at have diversitet i organisationen, også i forhold til, hvilket sind, vi har.(10:02) Hvorfor er danske elitevirksomheder smidt ud af klima-superligaen?Mangel på en detaljeret køreplan for den grønne omstilling har fået klimainitiativet Science Based Targets til at smide en række danske virksomheder af listen. Det er tilsyneladende vanskeligt for mange virksomheder at tage de næste skridt på vejen mod en grønnere forretning. Det er teknikaliteter, lyder det fra danske virksomheder, som godt nok anerkender, at det giver ridser i det grønne image.I studiet: Klimaredaktør Jakob Martini, journalist Sille Wulff Mortensen og ESG-redaktør Signe Ferslev.Teknik og lyddesign: Kasper Søegaard og Anders Thykier.

Join us for part 2 of BrainStorm's interview with Dr. Pierre Tariot, former Director for Banner Alzheimer's Institute and Co-Director of The International Alzheimer's Prevention Project. Host Meryl Comer asks Dr. Tariot, who has devoted his career to the care and study of people with or at risk for Alzheimer's disease, about the neuropsychiatric features of dementia. Dr. Tariot highlights the advancements in understanding and treating these behaviors associated with Alzheimer's.  You won't want to miss this episode. This episode is sponsored by Otsuka and Lundbeck.Support the show

By 2030, all baby boomers will be 65 years of age or older, equating to over 71 million people. As the aging population grows, a shortage of neurologists and geriatric doctors puts early diagnosis in jeopardy. In this episode of BrainStorm Dr. Pierre Tariot, former Director for Banner Alzheimer's Institute and Co-Director of The International Alzheimer's Prevention Project discussed the challenges of diagnosing and treating Alzheimer's disease with a shortage of neurologists. Host Meryl Comer and Dr. Tariot, who has devoted his career to the care and study of people with or at risk for Alzheimer's disease, talk about the importance of early detection for effective treatment. You won't want to miss this episode!This episode is sponsored by Otsuka and Lundbeck.Support the show

In this CME episode, Dr. Andrew Cutler interviews Dr. Dani Cabral about current and novel diagnostic tools and treatments for Alzheimer's disease. Optional CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CE credit, click nei.global/POD23-MDD Learning Objectives: After completing this educational activity, you should be better able to: Describe the potential role of multimodal imaging and biomarker strategies in the diagnostic process for Alzheimer's disease Assess the safety and efficacy of novel disease-modifying pharmacological treatments for Alzheimer's disease Describe potential future advancements in the diagnosis and treatment of Alzheimer's disease Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Credit Types: The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Associate: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cerevel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Neumora, Neurocrine, Noven, Otsuka, Relmada, Sage Therapeutics, Sunovion, Supernus, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alkermes, Axsome, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Pharma Interviewee Dani Cabral, MD Assistant Clinical Professor, Departments of Neurology and of Psychiatry, University of Arizona College of Medicine, Phoenix, AZ Dementia Specialist, Banner Sun Health Research Institute, Sun City, AZ Consultant/Advisor: Eisai, Lilly, Roche/Genentech Interview Questions Author Caroline L. O'Brien, MS Assistant Manager, Grant Development, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee, Content Editor, and Peer Reviewers have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Support: This activity is supported by an unrestricted educational grant from Eisai. Released: December 27, 2023      CE credit expires: December 27, 2026

In this CME episode, Dr. Andrew Cutler interviews Dr. Jeffrey Strawn about the role of pharmacogenomic testing in guiding treatment of major depressive disorder (MDD). They discuss how pharmacogenomic testing works, the impact of failed treatments and side effects on patients with MDD, and the clinical applications and future directions of pharmacogenomic testing. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD23-GEN Learning Objectives: After completing this educational activity, you should be better able to: Recognize the role of a patient's genetics in informing the efficacy and tolerability of antidepressants Consider opportunities to use pharmacogenomics as an evidence-based tool that can be employed to inform clinical decision making Implement pharmacogenomic testing to optimize patient outcomes, including symptom improvement, medication response, and remission rate Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Credit Types: The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Associate: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cerevel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Neumora, Neurocrine, Noven, Otsuka, Relmada, Sage Therapeutics, Sunovion, Supernus, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alkermes, Axsome, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Pharma Interviewee Jeffrey R. Strawn, MD Professor, Department of Psychiatry and Behavioral Neuroscience and Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH Grant/Research: Allergan/AbbVie Consultant/Advisor: Cerevel, Intra-Cellular, Otsuka Pre-Interview Author Gabriela Alarcón, PhD Senior Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee, Content Editor, and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Support: This activity is supported by an unrestricted educational grant from Myriad Genetics. Released: December 13, 2023      CME/CE credit expires: December 13, 2026

In this CME episode, Dr. Andrew Cutler interviews Dr. Vladimir Maletic about the impact of residual symptoms on patients with major depressive disorder, as well as treatment modifications to address residual symptoms in these individuals. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD23-MDD Learning Objectives: After completing this educational activity, you should be better able to: Describe the burden of residual symptoms in patients with major depressive disorder (MDD) Implement measurement-based care to assess residual MDD symptoms Modify treatment strategies to address residual MDD symptoms, including cognitive impairment, anhedonia, emotional blunting, and sexual dysfunction Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Credit Types: The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Associate: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cerevel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Neumora, Neurocrine, Noven, Otsuka, Relmada, Sage Therapeutics, Sunovion, Supernus, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alkermes, Axsome, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Pharma Interviewee Vladimir Maletic, MD, MS Clinical Professor, Department of Psychiatry and Behavioral Science, University of South Carolina School of Medicine Greenville, SC Consultant/ Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Biogen/Sage, Boehringer Ingelheim, Cervel, Intra-Cellular, Janssen, Jazz, Lundbeck, Neurelis, Neumora, Noven, Otsuka, Pax Medica, Relmada, Sunovion, Supernus, Takeda Speakers Bureau: AbbVie, Alfasigma, Alkermes, Axsome, Corium, Intracellular, Janssen, Lundbeck, Otsuka, Sunovion, Supernus, Takeda Pre-Interview Author Caroline L. O'Brien, MS Assistant Manager, Grant Development, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee, Content Editor, and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Support: This activity is supported by an unrestricted educational grant from Takeda. Released: November 29, 2023      CME/CE credit expires: November 29, 2026

The care partner perspective is essential to break through the silence and stigma of Alzheimer's disease. In this episode of BrainStorm host Meryl Comer continues her conversation with Leigh Callahan, a respected epidemiologist and researcher about caregiving. Her husband, Dr. John Winfield, had a distinguished career as a researcher and rheumatologist until Alzheimer's changed everything. Listen as Dr. Callahan reflects on the insight she gained as care partner of her husband throughout his Alzheimer's journey.This episode is sponsored by Otsuka and Lundbeck.Produced by Susan Quirk and Amber RonigerSupport the show

The care partner is the keeper of the secrets and their perspective is essential to break through the silence and stigma of Alzheimer's disease. In this episode of BrainStorm host Meryl Comer talks with Leigh Callahan, a respected epidemiologist and researcher focused on rheumatic disease. Her husband, Dr. John Winfield, had a distinguished career as a researcher and rheumatologist until Alzheimer's changed everything. Dr. Callahan shares her experience as she navigated her husband's journey, sharing that the first signs of disease - agitation, irritation, and frustration - are not typically identified as symptoms of Alzheimer's disease. Listen as they discuss the challenges before and after a diagnosis. This episode is sponsored by Otsuka and Lundbeck.Support the show

H. Lundbeck A/S v. Lupin Ltd.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/managing-tardive-dyskinesia-9045Featuring faculty Gregory Mattingly, MD, moderated by Gregg Sherman, MD.SummaryBesides identification of patients with Tardive Dyskinesia (TD), management options have not always provided much, if any, relief. Traditional approaches to managing TD were not only questionable, and some were potentially harmful, but the availability of newer medications has ushered in a new era in TD management. In this activity, discuss management principles and review two cases to put TD management into practice.This podcast was recorded and is being used with permission of the presenters.Learning ObjectiveUpon completion of this activity, learners should be able to:Individualize the management of TD using evidence-based strategies that target uncontrolled movementsThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).Summary of Individual DisclosuresAngela Golden has disclosed the following financial relationships:Consultant: SetPoint (obesity), WW (obesity)Advisor: Currax (obesity), Genesis (obesity), Lilly (obesity), Novo Nordisk (obesity), Acela (hypothyroidism)Speaker: Currax (obesity), Novo Nordisk (obesity)Receipt of Royalty: Amazon (fiction books), Springer (obesity book)Greg Mattingly has disclosed the following financial relationship:Consultant: AbbVie, Alkermes, Axsome, Biogen, Corium, Eisai, Ironshore, Intra-Cellular, Janssen, Lundbeck, Neurocrine Biosciences, Noven, Otsuka, Redax, Roche, Sage, Sirona, Sunovion, Supernus, Takeda, TevaSpeaker: AbbVie, Alkermes, Axsome, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine Biosciences, Noven, Otsuka, Sunovion, Supernus, Takeda, Tris PharmaContracted Research: AbbVie, Alkermes, Akili, Axsome, Boehringer Ingelheim, Emalex, Idorsia, Janssen, Karuna, Lumos Labs, Medgenics, Neurocrine Biosciences, NLS Pharmaceuticals, Otsuka, Redax, Relmada, Roche, Sage, Sirtsei, Sunovion, Supernus, Takeda, TevaAll his disclosures are related to mental healthFaculty, planners, guest patient(s) (if applicable), and moderators for this educational activity not listed in the Summary of Individual Disclosures above have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.Disclosure of Commercial Support This activity is supported by an independent medical education grant from Neurocrine Biosciences, Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/whos-at-risk-for-tardive-dyskinesia-9044 Featuring faculty Gregory Mattingly, MD, moderated by Gregg Sherman, MD. SummaryTardive Dyskinesia (TD) exerts a profound negative impact across a patient's life, including physical and cognitive domains and psychosocial functioning. This affects quality of life (QoL), increases hospitalizations and is associated with speech and eating difficulties, decreased employment, social withdrawal, stigmatization, and amplified emotional distress. In this podcast, hear from a patient who suffered with TD for years before diagnose, and discuss how to identify and support patients with TD.Learning ObjectivesUpon completion of this activity, learners should be able to:Identify the early manifestations of tardive dyskinesia (TD) in patients on antipsychotic therapyRecognize the burden associated with untreated TD and the consequences of delayed diagnosisThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0 hours of pharmacology).Summary of Individual DisclosuresAngela Golden has disclosed the following financial relationships:Consultant: SetPoint (obesity), WW (obesity)Advisor: Currax (obesity), Genesis (obesity), Lilly (obesity), Novo Nordisk (obesity), Acela (hypothyroidism)Speaker: Currax (obesity), Novo Nordisk (obesity)Receipt of Royalty: Amazon (fiction books), Springer (obesity book)Greg Mattingly has disclosed the following financial relationship:Consultant: AbbVie, Alkermes, Axsome, Biogen, Corium, Eisai, Ironshore, Intra-Cellular, Janssen, Lundbeck, Neurocrine Biosciences, Noven, Otsuka, Redax, Roche, Sage, Sirona, Sunovion, Supernus, Takeda, TevaSpeaker: AbbVie, Alkermes, Axsome, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine Biosciences, Noven, Otsuka, Sunovion, Supernus, Takeda, Tris PharmaContracted Research: AbbVie, Alkermes, Akili, Axsome, Boehringer Ingelheim, Emalex, Idorsia, Janssen, Karuna, Lumos Labs, Medgenics, Neurocrine Biosciences, NLS Pharmaceuticals, Otsuka, Redax, Relmada, Roche, Sage, Sirtsei, Sunovion, Supernus, Takeda, TevaAll his disclosures are related to mental healthFaculty, planners, guest patient(s) (if applicable), and moderators for this educational activity not listed in the Summary of Individual Disclosures above have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.Disclosure of Commercial Support This activity is supported by an independent medical education grant from Neurocrine Biosciences, Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

Efter et par negative børsdage tyder noget på, at vinden igen er ved at vende. Millionærklubben ser på sagen, dykker ned i dagens regnskabstal fra A. P. Møller - Mærsk og svarer på spørgsmål fra lytterne. Du kan høre mere om blandt andre Bavarian Nordic, Betsson, NKT, Brdr. Hartmann, Lundbeck, Bravida, Concordia Maritime, Norwegian, DNO, Aker BP, Vår Energi og Okea og ISS I studiet: Lau Svenssen, Lars Persson og Bodil Johanne Gantzel. See omnystudio.com/listener for privacy information.

In this CME episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl and Dr. Sarah Vinson about the ethicality and morality of involuntary treatment for serious mental illness (SMI), the relationship between SMI and the criminal justice system, and community-based changes that are being pursued to improve treatment and reduce the criminalization of SMI. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD23-SMI Learning Objectives: After completing this educational activity, you should be better able to: Recognize the neuroethics involved in involuntary treatment of serious mental illness Identify methods to prevent patients with serious mental illness from entering the criminal justice system, including the utility of diversion programs Institute community-based changes that have the potential to reduce the criminalization of serious mental illness, both on the individual and the policy level Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity does not pertain to pharmacology and is worth 0.0 continuing education hour of pharmacotherapeutics. Credit Types: The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Associate: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits™ Interprofessional Continuing Education: IPCE credit for learning and change Peer Review: The content was peer-reviewed by an MD specializing in forensic psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cerevel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Neumora, Neurocrine, Noven, Otsuka, Relmada, Sage Therapeutics, Sunovion, Supernus, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alkermes, Axsome, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Pharma Interviewees Stephen M. Stahl, MD, PhD, DSc (Hon.) Clinical Professor, Department of Psychiatry and Neuroscience, University of California, Riverside School of Medicine, Riverside, CA Adjunct Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA Honorary Visiting Senior Fellow, University of Cambridge, Cambridge, UK Editor-in-Chief, CNS Spectrums Director of Psychopharmacology Services, California Department of State Hospitals Grant/Research: Acadia, Alkermes, Allergan/AbbVie, Arbor, AssureX, AstraZeneca, Avanir, Axovant, Biogen, Boehringer Ingelheim Braeburn, BristolMyer Squibb, Celgene, CeNeRex, Cephalon, Daiichi Sankyo-Brazil, Dey, Eisai, Forest, Genomind, Glaxo Smith Kline, Harmony Biosciences, Indivior, Intra-Cellular, Ironshore, Janssen, JayMac, Jazz, Lilly, Lundbeck, Merck, Neurocrine, Neuronetics, Novartis, Otsuka, Pear, Pfizer, Reviva, Roche, Sage, Servier, Shire, Sprout, Sunovion, Supernus, Takeda, Teva, Tonix, Torrent, Vanda Consultant/Advisor: Acadia, Adamas, Alkermes, Allergan/AbbVie, Altus, Arbor, AstraZeneca, Avanir, Axovant, Axsome, Biogen, Biomarin, Biopharma, Celgene, Cerevel, ClearView, Clexio, Concert, DepotMed, Done, EMD Serono, Eisai, Enveric, Eurolink, Fabre-Kramer, Ferring, Forest, Gedeon Richter, Genetica, Genomind, Innovative Science Solutions, Impel, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Libbs, Lilly, Lipidio, Longboard, Lundbeck, Merck, Neos, NeuraWell, Neurocrine, NeuroPharma, Novartis, Noveida, Otsuka, Perrigo, Pfizer, Pierre Fabre, Proxymm, Recordati, Relmada, Reviva, Sage, Saniona, Servier, Shire, Sprout, Sunovion, Supernus, Takeda, Taliaz, Teva, Tonix, Tris, Trius, Vanda, Vertex, Viforpharma Speakers Bureau: Acadia, Allergan/AbbVie, Genentech, Janssen, Lundbeck, Merck, Neurocrine, Otsuka, Servier, Sunovion, Takeda, Teva Options Holdings: Delix, Genomind, Lipidio, NeuraWell Sarah Y. Vinson, MD, FAPA Interim Department Chair; Clinical Associate Professor; Director, Child and Adolescent Psychiatry Fellowship Program; Department of Psychiatry and Behavioral Sciences, Morehouse School of Medicine, Atlanta, GA Medical Director, Substance Abuse and Mental Health Services Administration (SAMHSA) African American Behavioral Health Center of Excellence, Atlanta, GA No financial relationships to disclose. Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Senior Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee, Content Editor, and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Support: This activity is supported by an unrestricted educational grant from Alkermes. Released: July 25, 2023      CME/CE credit expires: July 24, 2026

In this episode of The Mighty Podcast, host Ashley Kristoff speaks with Michele Novella, a psychiatric nurse practitioner as well as April and Tatiana, two individuals living with a type of depression called major depressive disorder (MDD). Together, they will share their personal journeys and highlight the power of finding your voice. This episode of The Mighty Podcast includes paid content from Takeda Pharmaceuticals and Lundbeck. Michele Novella is a paid consultant and Tatiana and April are paid contributors for Takeda Pharmaceuticals and Lundbeck. Podcast Transcript: https://bit.ly/3X4E88E Check Out These Resources: For Product Information, including Boxed Warning and Medication Guide: https://content.takeda.com/?contenttype=MEDGUIDE&product=TRI&language=ENG&country=GBL&documentnumber=1 For additional patient stories and resources:⁠ https://us.trintellix.com/patient-stories⁠ National Suicide Prevention Lifeline: Call or Text 988 Crisis Text Line: Text HOME to 741741

Det samlede analytikerkorps ser ikke ud til at være specielt positive på de amerikanske regnskaber her inden, tallene lander, men det kan faktisk være postivt for aktieudviklingen. Det mener i hvert fald dagens gæst i Millionærklubben, senior aktiestrateg Simon Kristiansen fra Nordea. Hør, hvorfor han ikke selv er helt så bekymret og få hans bud på, hvilke sektorer man særligt skal holde øje med. Med i studiet er også økonom og porteføljeforvalter Lau Svenssen, der bl.a. kommer forbi nyheder om Lundbeck og stemningen på det generelle marked. Vært: Bodil Johanne Gantzel.See omnystudio.com/listener for privacy information.

Listen to Amica Simmons-Yon, PharmD, PhD and Alyssa Peckham, PharmD, BCPP as they spill the tea on The Holiday Blues with special guest, Bennett Doughty, PharmD, BCPS, BCPP. During this episode, Dr. Doughty discusses mental health during the holiday season. Whether that's a worsening of a pre-existing condition or an emergence of new symptoms, Dr. Doughty walks us through some of the most common experiences and what we can do about them to persevere. Lastly, Dr. Doughty shares some key resources with listeners and where they can read more about this topic! Featuring: • Bennett Doughty, PharmD; Clinical Assistant Professor, Department of Pharmacy Practice, Binghamton School of Pharmacy and Pharmaceutical Sciences • Amica Simmons-Yon, PharmD, PhD; Clinical & Scientific Liaison, OPDC • Alyssa Peckham, PharmD, BCPP; Clinical & Scientific Liaison, OPDC Resources: • PsychU Article - Will Consumers Add Health Services To Their Holiday Shopping List? : bit.ly/3vQ0ZrT • PsychU Community Podcast - Burnout & Managing Stress: bit.ly/3QvHZsb • PsychU Article - Over Half Of Adults In The U.S. Are Considered ‘Lonely': bit.ly/3Gvl6kc • PsychU Article - Severe Loneliness Can Increase Health Care Costs By Over $300 Per Month: bit.ly/3XkNtZg • PsychU Article - Is Loneliness The Overlooked Social Determinant?: bit.ly/3imjTnl • PsychU Video - Digital Technologies For Substance Use Disorder: bit.ly/3WVWyYH • PsychU Downloadable Resource - Substance Use Disorders & Mental Health: bit.ly/3jWP4pr • PsychU Downloadable Resource - Fact Sheet: The Eight Dimensions of Wellness: bit.ly/3XkNQ66 • PsychU Resource Library - Suicide Awareness: bit.ly/3XkNRHc Disclaimers: Bennett Doughy, PharmD is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc  Amica Simmons-Yon & Alyssa Peckham are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU's contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU's educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.

Genåbningen i Kina byder på flere interessante investeringsmuligheder, og dem deler Lars Tvede, mangeårig investor og chef for hedgefonden Atlas Global Macro, ud af i mandagens millionærklubben. Vi har også Jacob Pedersen, aktieanalysechef i Sydbank, med på telefon til en snak om de kommende regnskab, og hvad vi kan forvente af 2023. Klubbens egen forvalter, Lau Svenssen, giver en overflyvning af dagens marked. Vært: Sara Sjølin.  I dagens afsnit kan du også høre om bl.a. Lundbeck, Danske Bank, Billiton, Glencore, Mærsk, Philips, Disney, Rockwool og Posco. See omnystudio.com/listener for privacy information.

2023 er skudt i gang med flotteaktiestigninger, men kan de blive ved, og hvor finder man de bedste afkast? Det snakker Sara Sjølin med Henrik Henriksen, chefstrateg hos Petersen & Partners, om i dagens Millionærklubben. Vi vender også Teslas kurstæsk og Apples røde start på det nye år sammen med klubbens egen forvalter Michael Friis Jørgensen. I dagens afsnit kan du også høre om bl.a. Royal Unibrew, Novo Nordisk, Berkshire Grey, Lundbeck og Demant.See omnystudio.com/listener for privacy information.

We totaled the salaries, stock options and bonuses awarded to various medtech CEOs to figure out who the highest paid chiefs were. And our top 10 list saw a few ups and downs over the past year. We'll hear from Connor Hale and Andrea Park as they discuss medtech's highest paid CEOs. Also in this episode, we cover the week's biggest headlines including Theranos' COO's jail sentence, highlights from the American Society of Hematology annual meeting, and an update on the Horizon Therapudics bidding war.  To learn more about topics in this episode: Fierce JPM Week  The top 10 highest-paid medtech CEOs Fierce Biotech's ASH 2022 Coverage Fierce Pharma's ASH 2022 Coverage Theranos' Sunny Balwani lands 13-year fraud sentence after ex-partner Elizabeth Holmes gets 11 years Watch out, Amgen. Mirati kicks off KRAS showdown with FDA approval for Krazati  FDA advisers nix Cytokinetics' heart failure med, rejecting argument for subgroup use  Buyout on Horizon: Amgen floats $28B offer for rare disease drug maker as Sanofi exits bidding war  Sanofi started—and lost—$28B bidding war for Horizon. Is the company's M&A appetite still rumbling?  AstraZeneca, Biogen, Daiichi, Lundbeck, UCB all hit with drug marketing breaches, but highest censure reserved for Novo Nordisk "The Top Line" is produced by senior multimedia producer Teresa Carey with managing editor Querida Anderson and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.

A pair of neurology companies are in the spotlight on the latest edition of the BioCentury This Week podcast. BioCentury's editors assess how Lundbeck has evolved in the past five years, with a fresh emphasis on first in class in its revamped pipeline, and how Biogen could acquire its way into being a near-term growth company. BioCentury's editors also discuss the Biden administration's initiative that seeks to compensate for decades of underinvestment in the nation's biomanufacturing capacity and takeaways from Nora Volkow, director of NIH's National Institute on Drug Abuse, during her appearance last week on The BioCentury Show.

  In this CME episode, Dr. Andrew Cutler interviews Dr. Vladimir Maletic about novel agents in development for Major Depressive Disorder or MDD. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-MDD. Learning Objectives: After completing this educational activity, you should be better able to: Describe novel mechanisms of action of agents under investigation for the treatment of depression Explain the potential implications of novel rapid-acting and multi-modal agents in optimizing outcomes for patients with unipolar depression Integrate newly available options for depression into clinical practice Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.   A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics. Credit Types. The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Assistant: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Mental Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any potential conflicts of interest were identified and mitigated prior to the activity being planned, developed, or presented. InterviewerAndrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie/Allergan, Acadia, Alfasigma, Biogen, BioXcel, Boehringer Ingelheim, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, Neurocrine, Noven, Otsuka, Relmada, Sage, Sunovion, Supernus, Teva Speakers Bureau: AbbVie/Allergan, Acadia, Alfasigma, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Teva   IntervieweeVladimir Maletic, MD, MS Clinical Professor of Psychiatry, University of South Carolina School of Medicine, Greenville, SC Consultant/Advisor: AbbVie, Alfasigma, Alkermes, Biogen/Sage, Intracellular, Ironshore, Janssen, Lundbeck, Otsuka, Relmada, Sunovion, Supernus, Takeda Speakers Bureau: AbbVie, Alfasigma, Alkermes, Biogen/Sage, Intracellular, Ironshore, Janssen, Lundbeck, Otsuka, Sunovion, Supernus, Takeda   Pre-Interview AuthorSabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose.   The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competency and strategies for understanding and reducing the impact of implicit bias can be found in this handout. Support: This activity is supported by an unrestricted educational grant from Sage Therapeutics, Inc. Released: September 26, 2022     CME/CE credit expires: September 26, 2025

Listen to Amica Simmons-Yon, PharmD, PhD and Alyssa Peckham, PharmD, BCPP as they spill the tea on Suicide Awareness & Prevention with special guest, Dr. Mauricio Tohen. During this episode, Dr. Tohen highlights the importance of suicide awareness and prevention. He will discuss current trends in mental health and suicide rates, and specific behaviors and triggers that increase risk of suicide especially concerning youth/adolescents and individuals living with bipolar disorder. Our special guest will even spill the tea on where we can find helpful resources on our efforts in Suicide Awareness and Prevention! Dr. Mauricio Tohen is a Distinguished University Professor at the University of New Mexico and the Chairman of the University of New Mexico's Department of Psychiatry and Behavioral Sciences. He has more than 350 publications, 20,000 scientific citations, several books, and prestigious awards to his name. Dr. Tohen has also been recognized as one of the world's leading experts on bipolar disorder on the breadth and depth of his publications, and one of 100 scientists worldwide recognized in the Psychiatry/Psychology category. Featuring: • Mauricio Tohen, MD, DrPH, MBA; Professor & Chairman at the University of New Mexico Health Sciences Center Department of Psychiatry • Amica Simmons-Yon, PharmD, PhD; Clinical & Scientific Liaison, OPDC • Alyssa Peckham, PharmD, BCPP; Clinical & Scientific Liaison, OPDC   Links: PsychU - Suicide Awareness: https://bit.ly/3zUA003 PsychU - Bipolar Disorder: https://bit.ly/3JXPJA8 PsychU - Suicide Prevention Brochure: https://bit.ly/3w0PM8h PsychU - Youth Suicide Prevention - Jonathan Singer: https://bit.ly/3bSaSz4 Home | AFSP: https://afsp.org/ PsychU - Hot Topics: Clinical Questions In Bipolar Disorder (Part 1): https://bit.ly/3QA4eMk PsychU - A Shot For Bipolar I Disorder? Identifying Appropriate Patient Profiles For Maintenance Therapy With Long Acting Injectable Medications: https://bit.ly/3C2HDV0 PsychU - California, Georgia, Indiana, New Jersey, Oklahoma & Virginia Saw Increase In Adolescent Suicides During COVID-19: https://bit.ly/3bT6hN0 PsychU - Children & Adolescents Experiencing Double The Rate Of Depression & Anxiety Due To COVID-19: https://bit.ly/3PmIHWq Mauricio Tohen is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc Amica Simmons-Yon & Alyssa Peckham are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU's contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU's educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.

Listen to Amica Simmons-Yon, PharmD, PhD and Alyssa Peckham, PharmD, BCPP as they spill the tea on the impact of racism in the mental healthcare community with special guest, Dr. Gonzalo Gonzalez. As we know, the effects of racism are not confined to patients alone--but also impacts mental health professionals and researchers. During this episode, Dr. Gonzalez will highlight a recent webinar featuring himself and Dr. Napoleon Higgins where they discussed barriers that healthcare professionals experience, including BIPOC and other marginalized groups. Dr. Gonzalez will also discuss his personal experience with racism, where we've been, where we are currently, and strategies the health care and research communities are implementing to address some of these challenges. Dr. Gonzalez currently is a Nephrology Clinical & Scientific Liaison in Medical Affairs at Otsuka Pharmaceutical Development & Commercialization, Inc. He most recently served as a COVID-19 Medical & Scientific Expert for the CDC Foundation and was a leader for Prevention & Control at the City of Detroit Health Department. Featuring: • Gonzalo Gonzalez, DNP, APRN, NP-C Nephrology Clinical & Scientific Liaison, Otsuka Pharmaceutical Development & Commercialization, Inc. • Amica Simmons-Yon, PharmD, PhD; Clinical & Scientific Liaison, OPDC • Alyssa Peckham, PharmD, BCPP; Clinical & Scientific Liaison, OPDC Links: PsychU - The Effects Of Racism On The Mental Healthcare Community: How Marginalized Patients & Providers Are Impacted: https://psychu.org/the-effects-of-racism-on-the-mental-healthcare-community-how-marginalized-patients-providers-are-impacted/ PsychU - Diversity, Equity, & Inclusion: https://bit.ly/3QC4KJZ PsychU - Impact & Trauma Of Racism: https://bit.ly/3phceqc PsychU - Lifespan Impact Of Racism-Related Stress: https://bit.ly/3AhPFHY PsychU - Intergenerational Effects Of Racism: https://bit.ly/3w0ndrI PsychU - The 12 Steps To Inclusivity In Mental Health Services Infographic: https://bit.ly/3zSAXGf PsychU - Call To Action: The Need For Stigma Awareness In Healthcare Professional Education: https://bit.ly/3dludsF Suicide & Black Americans: Statistics, Faith, & Contextual Competence: https://bit.ly/3pgoJSO PsychU - Spotlight On Minority Mental Health Month: A Conversation With Dr. Napoleon B. Higgins Jr.: https://bit.ly/3BYr5x5 Amica Simmons-Yon, Alyssa Peckham, and Gonzalo Gonzalez are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU's contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU's educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.

Listen to Amica Simmons-Yon, PharmD, PhD and Alyssa Peckham, PharmD, BCPP as they spill the tea on Minority Mental Health Awareness with special guest, Dr. Carolyn Jones. During this episode, Dr. Jones highlights the importance of mental health awareness in minority communities, educational gaps and needs within the mental health space, and opportunities to reduce stigma amongst minority men for optimal mental wellness. Dr. Jones most recently retired from Otsuka as a Senior Medical Science Liaison after 22 years of providing medical education and resources to healthcare professionals. Currently, Carolyn Jones, PhD stays active and very busy as a Board Member for NAMI Florida, which is the state affiliate of the National Alliance on Mental Illness. Featuring: • Carolyn Jones, PhD; Board Member of NAMI Florida, state affiliate of the National Alliance on Mental Illness • Amica Simmons-Yon, PharmD, PhD; Clinical & Scientific Liaison, OPDC • Alyssa Peckham, PharmD, BCPP; Clinical & Scientific Liaison, OPDC Links: PsychU - Diversity, Equity, & Inclusion: https://bit.ly/3w0UXoL PsychU - The Effects Of Racism On The Mental Healthcare Community: How Marginalized Patients & Providers Are Impacted: https://psychu.org/the-effects-of-racism-on-the-mental-healthcare-community-how-marginalized-patients-providers-are-impacted/ PsychU - 2022 BIPOC Mental Health Month Toolkit: https://bit.ly/3PiPn8g PsychU - Intergenerational Effects Of Racism: https://bit.ly/3AfTVb0 PsychU - Call To Action: The Need For Stigma Awareness In Healthcare Professional Education: https://bit.ly/3C1AbJu PsychU - Suicide & Black Americans: Statistics, Faith, & Contextual Competence: https://bit.ly/3JXoxBp PsychU - Spotlight On Minority Mental Health Month: A Conversation With Dr. Napoleon B. Higgins Jr.: https://bit.ly/3QgLRwi PsychU - Impact & Trauma Of Racism: https://bit.ly/3AkAsGp Carolyn Jones is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc Amica Simmons-Yon & Alyssa Peckham are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU's contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU's educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.